MBIP

Summary

MBIP (MAP3K12 binding inhibitory protein 1, HGNC:20427) is a protein-coding gene on chromosome 14q13.3, encoding MAP3K12-binding inhibitory protein 1 (Q9NS73). Functions as part of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4.

Enables identical protein binding activity and protein kinase inhibitor activity. Involved in several processes, including positive regulation of JNK cascade; regulation of cell division; and regulation of gene expression. Located in cytosol; nucleolus; and nucleoplasm. Part of ATAC complex.

Source: NCBI Gene 51562 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 43 total
• MANE Select transcript: NM_016586

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20427
Approved symbol	MBIP
Name	MAP3K12 binding inhibitory protein 1
Location	14q13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151332
Ensembl biotype	protein_coding
OMIM	609431
Entrez	51562

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 22 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000318473, ENST00000359527, ENST00000416007, ENST00000603139, ENST00000603913, ENST00000604154, ENST00000604160, ENST00000604336, ENST00000604768, ENST00000605579, ENST00000905196, ENST00000905197, ENST00000905198, ENST00000905199, ENST00000905200, ENST00000905201, ENST00000905202, ENST00000917537, ENST00000917538, ENST00000917539, ENST00000917540, ENST00000917541, ENST00000950007, ENST00000950008, ENST00000950009

RefSeq mRNA: 3 — MANE Select: NM_016586 NM_001144891, NM_001308110, NM_016586

CCDS: CCDS45096, CCDS76672, CCDS9658

Canonical transcript exons

ENST00000416007 — 9 exons

Exon	Start	End
ENSE00000998963	36316693	36316812
ENSE00000998964	36314691	36314915
ENSE00001278113	36314512	36314608
ENSE00001278158	36320460	36320637
ENSE00003469317	36311959	36312024
ENSE00003471478	36311573	36311725
ENSE00003582723	36298564	36299190
ENSE00003619138	36308092	36308189
ENSE00003630186	36300785	36300823

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 96.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.0272 / max 435.8170, expressed in 1770 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
142918	14.1123	1764
142919	0.5588	300
142917	0.3561	80

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left lobe of thyroid gland	UBERON:0001120	96.69	gold quality
right lobe of thyroid gland	UBERON:0001119	96.49	gold quality
thyroid gland	UBERON:0002046	96.22	gold quality
right lung	UBERON:0002167	95.24	gold quality
upper lobe of left lung	UBERON:0008952	94.76	gold quality
upper lobe of lung	UBERON:0008948	94.74	gold quality
oocyte	CL:0000023	94.12	gold quality
secondary oocyte	CL:0000655	93.28	gold quality
adenohypophysis	UBERON:0002196	92.64	gold quality
lung	UBERON:0002048	92.57	gold quality
lower lobe of lung	UBERON:0008949	92.46	gold quality
body of stomach	UBERON:0001161	92.26	gold quality
calcaneal tendon	UBERON:0003701	91.77	gold quality
fundus of stomach	UBERON:0001160	91.36	gold quality
skin of abdomen	UBERON:0001416	91.23	gold quality
rectum	UBERON:0001052	91.15	gold quality
descending thoracic aorta	UBERON:0002345	90.82	gold quality
stomach	UBERON:0000945	90.61	gold quality
left ovary	UBERON:0002119	90.54	gold quality
tibial nerve	UBERON:0001323	90.28	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.13	gold quality
popliteal artery	UBERON:0002250	90.12	gold quality
tibial artery	UBERON:0007610	90.12	gold quality
pituitary gland	UBERON:0000007	90.07	gold quality
right ovary	UBERON:0002118	89.93	gold quality
aorta	UBERON:0000947	89.78	gold quality
ovary	UBERON:0000992	89.75	gold quality
endocervix	UBERON:0000458	89.67	gold quality
thoracic aorta	UBERON:0001515	89.49	gold quality
ascending aorta	UBERON:0001496	89.47	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8894	yes	491.31
E-GEOD-130148	yes	12.65
E-GEOD-93593	yes	7.12
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
MMP1	Activation
MMP13	Activation
MMP7	Activation
MMP9	Activation

miRNA regulators (miRDB)

73 targeting MBIP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509

Literature-anchored findings (GeneRIF, showing 2)

• Pathway-Affecting Single Nucleotide Polymorphisms (SNPs) in RPS6KA1 and MBIP Genes are Associated with Breast Cancer Risk. (PMID:32711446)
• MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs. (PMID:32963352)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mbip	ENSDARG00000019364
mus_musculus	Mbip	ENSMUSG00000021028
rattus_norvegicus	Mbip	ENSRNOG00000008610
drosophila_melanogaster	CG12016	FBGN0035436

Paralogs (3): NMRK2 (ENSG00000077009), NMRK1 (ENSG00000106733), MOCS2 (ENSG00000164172)

Protein

Protein identifiers

MAP3K12-binding inhibitory protein 1 — Q9NS73 (reviewed: Q9NS73)

Alternative names: MAPK upstream kinase-binding inhibitory protein

All UniProt accessions (5): Q9NS73, S4R2X9, S4R3N2, S4R3P6, S4R3Y0

UniProt curated annotations — full annotation on UniProt →

Function. Functions as part of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. Inhibits the MAP3K12 activity to induce the activation of the JNK/SAPK pathway. Together with MOCS2B, inhibits the activity of stress kinase EIF2AK2/PKR; this may lead to effects such as suppression of JNK activation and subsequent stress-responsive transcription, or suppression of eIF2a phosphorylation to favor translation.

Subunit / interactions. Component of the ADA2A-containing complex (ATAC), composed of KAT14, KAT2A, TADA2L, TADA3L, ZZ3, MBIP, WDR5, YEATS2, CCDC101 and DR1. In the complex, it probably interacts directly with KAT2A, KAT14 and WDR5. Interacts with the molybdopterin synthase complex subunit MOCS2B; the interaction is direct and enhances the interaction between MBIP and protein kinase EIF2AK2/PKR. Interacts with protein kinase EIF2AK2/PKR; the interaction is direct and leads to inhibition of EIF2AK2 self-activating autophosphorylation. Interacts with the molybdopterin synthase complex subunit MOCS2A.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Ubiquitous. High expression seen in the heart and lung.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9NS73-1	1	yes
Q9NS73-2	2
Q9NS73-3	3
Q9NS73-5	4

RefSeq proteins (3): NP_001138363, NP_001295039, NP_057670* (*=MANE)

Domains & families (InterPro)

UniProt features (21 total): cross-link 9, region of interest 3, splice variant 3, sequence variant 2, modified residue 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS73-F1	68.83	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 153, 235, 301, 304, 325, 91, 301, 94, 118, 129, 139

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-9772755	Formation of WDR5-containing histone-modifying complexes
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization
R-HSA-74160	Gene expression (Transcription)
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 141 (showing top): GOBP_REGULATION_OF_PROTEIN_DEACETYLATION, GOBP_MACROMOLECULE_DEACYLATION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, CEBPB_01, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, GOBP_JNK_CASCADE, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_DIVISION, TGACATY_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, CREB_Q3, ACTTTAT_MIR1425P, GOBP_EMBRYO_DEVELOPMENT, GOBP_REGULATION_OF_EMBRYONIC_DEVELOPMENT

GO Biological Process (8): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of gene expression (GO:0010628), regulation of embryonic development (GO:0045995), positive regulation of JNK cascade (GO:0046330), regulation of cell division (GO:0051302), regulation of cell cycle (GO:0051726)

GO Molecular Function (3): protein kinase inhibitor activity (GO:0004860), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (7): nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), mitotic spindle (GO:0072686), ATAC complex (GO:0140672), nucleus (GO:0005634), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Gene expression (Transcription)	1
Chromatin organization	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
transcription by RNA polymerase II	2
regulation of gene expression	2
regulation of cellular process	2
nuclear lumen	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
embryo development	1
regulation of multicellular organismal development	1
JNK cascade	1
positive regulation of MAPK cascade	1
regulation of JNK cascade	1
cell division	1
cell cycle	1
protein kinase activity	1
kinase inhibitor activity	1
protein kinase regulator activity	1
protein binding	1
binding	1
intracellular membraneless organelle	1
cytoplasm	1
spindle	1
SAGA-type complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

696 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MBIP	MAP3K12	Q12852	891
MBIP	YEATS2	Q9ULM3	854
MBIP	DR1	Q01658	842
MBIP	ZZZ3	Q8IYH5	758
MBIP	POLE4	Q9NR33	727
MBIP	WDR5	P61964	713
MBIP	POLE3	Q9NRF9	671
MBIP	TADA2A	O75478	661
MBIP	SGF29	Q96ES7	645
MBIP	TADA3	O75528	571
MBIP	CATSPERH	E9PQX1	552
MBIP	CAPNS2	Q96L46	538
MBIP	PRDM11	Q9NQV5	514
MBIP	ITPK1	Q13572	505
MBIP	KAT2A	Q92830	501

IntAct

144 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
WDR5	KMT2D	psi-mi:“MI:0914”(association)	0.910
WDR5	MBIP	psi-mi:“MI:0915”(physical association)	0.880
KAT14	MBIP	psi-mi:“MI:0915”(physical association)	0.860
MBIP	KAT14	psi-mi:“MI:0915”(physical association)	0.860
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
SGF29	NDC80	psi-mi:“MI:0914”(association)	0.840
MED23	MED19	psi-mi:“MI:2364”(proximity)	0.770
WDR5	MEN1	psi-mi:“MI:0914”(association)	0.710
MBIP	TXLNB	psi-mi:“MI:0915”(physical association)	0.670
TXLNB	MBIP	psi-mi:“MI:0915”(physical association)	0.670
HSPB2	BAG3	psi-mi:“MI:0914”(association)	0.670
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
EPB41L3	MBIP	psi-mi:“MI:0915”(physical association)	0.620
MBIP	MBIP	psi-mi:“MI:0915”(physical association)	0.620
MBIP	PLEKHF2	psi-mi:“MI:0915”(physical association)	0.620
PPFIA1	MBIP	psi-mi:“MI:0915”(physical association)	0.620
FXR2	MBIP	psi-mi:“MI:0915”(physical association)	0.620
MBIP	EGFR	psi-mi:“MI:0915”(physical association)	0.620
MBIP	EGFR	psi-mi:“MI:2364”(proximity)	0.620

BioGRID (295): MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MBIP (Two-hybrid), MIS18A (Two-hybrid), CSRP2BP (Two-hybrid), MOAP1 (Two-hybrid), PLEKHF2 (Two-hybrid), NDEL1 (Two-hybrid)

ESM2 similar proteins: A0A2R8Q3S9, A2VCV0, A9ULX8, E1BN97, F1NVK6, F6UF99, P28236, P79169, P79368, Q06220, Q09108, Q0P557, Q0VA42, Q1LZF8, Q28132, Q29030, Q2T9I9, Q3B7T8, Q3V0J1, Q5PQX1, Q5R6R3, Q5T5J6, Q5ZM60, Q640L3, Q640U0, Q66H73, Q6PAV5, Q6PG04, Q7ZX27, Q7ZXV6, Q8K4Q9, Q8N4S0, Q8TDY2, Q90314, Q90WN7, Q91892, Q921T2, Q95M19, Q95MD2, Q95N18

Diamond homologs: A1CJM9, A1D7X4, A2QF55, A2X0R4, A4FUY7, A6R104, A7EVF4, B0X1V5, B0XYQ4, B2WBW4, B3M268, B3P6R5, B4GE20, B4IJG7, B4JHP4, B4KBH3, B4LVP8, B4NJW0, B4PUD1, B4QUC0, B5FXU9, D4GSW7, O22827, O31705, O67928, O96007, P30749, P45308, P65396, P65397, P65398, P65399, P65400, P65401, P9WJR2, P9WJR3, Q0V713, Q171H3, Q1DGL6, Q1DQS9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 137 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of WDR5-containing histone-modifying complexes	8	21.9×	2e-06
Epigenetic regulation by WDR5-containing histone modifying complexes	8	12.7×	5e-05
Deactivation of the beta-catenin transactivating complex	5	12.0×	4e-03
Proteasome assembly	5	10.5×	6e-03
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	5	10.2×	7e-03
Formation of the beta-catenin:TCF transactivating complex	7	8.7×	2e-03
Epigenetic regulation of gene expression	11	8.1×	4e-05
TCF dependent signaling in response to WNT	6	7.3×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cell division	5	30.4×	1e-04
regulation of embryonic development	7	18.4×	4e-05
transcription initiation-coupled chromatin remodeling	5	15.2×	2e-03
regulation of G1/S transition of mitotic cell cycle	6	14.6×	5e-04
positive regulation of myoblast differentiation	5	14.5×	2e-03
positive regulation of fibroblast proliferation	5	11.7×	6e-03
regulation of DNA repair	5	11.0×	8e-03
transcription by RNA polymerase II	11	6.2×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1719 predictions. Top by Δscore:

Variant	Effect	Δscore
14:36300779:ACTT:A	donor_loss	1.0000
14:36300781:TTACT:T	donor_loss	1.0000
14:36300782:TA:T	donor_loss	1.0000
14:36300783:A:AC	donor_gain	1.0000
14:36300784:C:CA	donor_gain	1.0000
14:36300819:AAGCT:A	acceptor_gain	1.0000
14:36300820:AGCT:A	acceptor_gain	1.0000
14:36300822:CT:C	acceptor_gain	1.0000
14:36300822:CTCTA:C	acceptor_loss	1.0000
14:36300824:C:CC	acceptor_gain	1.0000
14:36300824:CT:C	acceptor_loss	1.0000
14:36300825:T:A	acceptor_loss	1.0000
14:36300829:T:C	acceptor_gain	1.0000
14:36300829:T:TC	acceptor_gain	1.0000
14:36308088:TCAC:T	donor_gain	1.0000
14:36308090:A:AC	donor_gain	1.0000
14:36308091:C:CC	donor_gain	1.0000
14:36308091:CTA:C	donor_gain	1.0000
14:36314507:GTTA:G	donor_loss	1.0000
14:36314508:TTACC:T	donor_loss	1.0000
14:36314509:TACCT:T	donor_loss	1.0000
14:36314510:ACCTT:A	donor_loss	1.0000
14:36314511:CCTT:C	donor_loss	1.0000
14:36314542:C:A	donor_gain	1.0000
14:36314605:CAAT:C	acceptor_gain	1.0000
14:36314608:TC:T	acceptor_loss	1.0000
14:36314609:C:CA	acceptor_loss	1.0000
14:36314609:C:CC	acceptor_gain	1.0000
14:36314689:A:AC	donor_gain	1.0000
14:36314690:C:CC	donor_gain	1.0000

AlphaMissense

2274 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:36314537:A:C	F182L	1.000
14:36314537:A:T	F182L	1.000
14:36314538:A:C	F182C	1.000
14:36314538:A:G	F182S	1.000
14:36314539:A:G	F182L	1.000
14:36314585:A:C	F166L	1.000
14:36314585:A:T	F166L	1.000
14:36314587:A:G	F166L	1.000
14:36308132:A:G	L283P	0.999
14:36308144:T:A	E279V	0.999
14:36308147:A:G	L278P	0.999
14:36311608:A:G	L252P	0.999
14:36311701:C:T	G221E	0.999
14:36311709:A:C	N218K	0.999
14:36311709:A:T	N218K	0.999
14:36311968:G:C	H210D	0.999
14:36311969:A:C	S209R	0.999
14:36311969:A:T	S209R	0.999
14:36311971:T:G	S209R	0.999
14:36312000:G:T	A199E	0.999
14:36312001:C:G	A199P	0.999
14:36312008:T:A	R196S	0.999
14:36312008:T:G	R196S	0.999
14:36312009:C:G	R196T	0.999
14:36312010:T:C	R196G	0.999
14:36314549:G:C	N178K	0.999
14:36314549:G:T	N178K	0.999
14:36314569:C:G	A172P	0.999
14:36314573:C:A	K170N	0.999
14:36314573:C:G	K170N	0.999

dbSNP variants (sampled 300 via entrez): RS1000066679 (14:36310592 G>A), RS1000234271 (14:36304957 A>G), RS1000357909 (14:36306694 A>T), RS1000538148 (14:36312360 A>C), RS1000610255 (14:36320193 G>C), RS1000626997 (14:36306647 C>T), RS1000678578 (14:36321684 T>C), RS1000683214 (14:36299205 G>A), RS1000979423 (14:36306455 T>C), RS1001199562 (14:36300704 T>C), RS1001314061 (14:36300357 A>G), RS1001407292 (14:36307089 T>A), RS1001429146 (14:36307390 T>G), RS1001569933 (14:36315712 C>T), RS1001573963 (14:36321827 G>C)

Disease associations

OMIM: gene MIM:609431 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001382_3	Thyroid cancer	5.000000e-11
GCST001856_13	Thyroid hormone levels	1.000000e-08
GCST008165_12	Thyroid stimulating hormone levels	5.000000e-11
GCST008828_3	Hypertension	7.000000e-06
GCST010653_76	Thyroid stimulating hormone levels	8.000000e-30

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	2
perfluorooctane sulfonic acid	decreases expression	2
Valproic Acid	decreases expression	2
FR900359	decreases phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
coumarin	increases phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Zoledronic Acid	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Catechin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Quercetin	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Asbestos, Crocidolite	affects expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.